Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Fibroadenoma and fibroepithelial lesions

Essential points for quick revision.

Saved on this device

Synopsis

Distinguish a concordant fibroadenoma from cellular fibroepithelial lesions and phyllodes tumour, then select observation, further sampling or excision according to diagnostic certainty, growth and patient priorities.

  • A fibroadenoma is a benign biphasic lesion containing epithelial and stromal elements; it commonly presents as a well-defined mobile mass in a younger patient.
  • Rapid enlargement, large size, older age at presentation or imaging-pathology discordance raises concern for a phyllodes tumour or another diagnosis, even when a previous core suggested fibroadenoma.
  • Triple assessment must be concordant: the clinical mass, radiological target and sampled tissue should describe the same lesion and support the same benign explanation.

Investigation priorities

01
Targeted ultrasoundFirst step

Characterise a palpable fibroepithelial lesion and provide a route for representative needle sampling.

Management branches

Assessment pathwayManage a new circumscribed breast mass

A 24-year-old presents with a 2 cm mobile breast mass that has not changed over four months and has no skin, nipple or nodal abnormality.

  1. Map the lump clinically and ask about growth, pregnancy, hormone exposure, previous masses and family history, while avoiding a definitive benign label from mobility alone.
  2. Arrange targeted imaging; if ultrasound shows a classic benign mass, decide with the breast team whether age, appearance and local protocol require core confirmation.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 8 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 8 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom